Vascular Biology Group, ANZAC Research Institute, New South Wales, Australia.
J Thromb Haemost. 2010 Mar;8(3):472-81. doi: 10.1111/j.1538-7836.2009.03716.x. Epub 2009 Dec 7.
EMMPRIN (CD147) is a matrix metalloproteinase inducer present on leukocytes and recently identified on platelets in vitro. We examined platelet CD147 expression in vivo and in correlation with markers of platelet activation and coronary artery disease (CAD).
PATIENTS/METHODS: This prospective observational study involved 70 subjects (55 patients with CAD and 15 controls). Platelet CD62P expression, PAC-1 expression, platelet-leukocyte aggregates and CD147 (both platelet and leukocyte) expression were assessed by flow cytometry, and soluble CD62P expression was assessed by enzyme-linked immunosorbent assay. A full blood count and high-sensitivity C-reactive protein test were performed.
CD147 was expressed on 20.45% +/- 1.63% (mean +/- standard error of the mean) of circulating platelets, whereas CD62P and PAC-1 were expressed on 0.87% +/- 0.12% and 0.90% +/- 0.27% of platelets, respectively. Platelet CD147 expression correlated with CD62P expression (r = 0.359, P = 0.002), PAC-1 expression (r = 0.428, P < 0.001), leukocyte CD147 expression (monocyte, r = 0.416, P = 0.001; granulocyte, r = 0.434, P < 0.001), C-reactive protein level and neutrophil/lymphocyte ratio (NLR). CAD patients had significantly higher CD147 mean fluorescence intensity than controls on circulating platelets (2.41 +/- 0.14 vs. 2.87 +/- 0.09, P = 0.014), monocytes (8.57 +/- 1.20 vs. 12.3 +/- 0.57, P = 0.006) and granulocytes (4.30 +/- 0.65 vs. 6.50 +/- 0.34, P = 0.005). Age adjustment eliminated the association between platelet CD147 expression and CAD, but the association between leukocyte CD147 expression and CAD persisted. According to multivariate analysis, the independent predictors of platelet CD147 expression were monocyte CD147 expression, NLR and age.
Platelet CD147 expression is evident in vivo and correlates moderately with traditional platelet activation markers and leukocyte CD147 expression. Platelet CD147 expression shows a stronger association with age, and leukocyte CD147 expression a stronger association with clinical CAD, suggesting differences in the regulation of platelet and leukocyte CD147 expression in vivo.
EMMPRIN（CD147）是一种存在于白细胞上的基质金属蛋白酶诱导剂，最近在体外也被鉴定为血小板上的标志物。我们检测了体内血小板 CD147 的表达情况，并将其与血小板活化标志物和冠状动脉疾病（CAD）进行了相关性分析。
患者/方法：这项前瞻性观察研究纳入了 70 名受试者（55 名 CAD 患者和 15 名对照者）。通过流式细胞术评估血小板 CD62P 表达、PAC-1 表达、血小板-白细胞聚集体和血小板及白细胞 CD147 表达，通过酶联免疫吸附试验评估可溶性 CD62P 表达。同时进行全血细胞计数和高敏 C 反应蛋白检测。
循环血小板上表达的 CD147 占 20.45%±1.63%（平均值±标准误），而 CD62P 和 PAC-1 分别占血小板的 0.87%±0.12%和 0.90%±0.27%。血小板 CD147 表达与 CD62P 表达（r=0.359，P=0.002）、PAC-1 表达（r=0.428，P<0.001）、白细胞 CD147 表达（单核细胞，r=0.416，P=0.001；粒细胞，r=0.434，P<0.001）、C 反应蛋白水平和中性粒细胞/淋巴细胞比值（NLR）呈正相关。CAD 患者循环血小板、单核细胞和粒细胞上的 CD147 平均荧光强度均显著高于对照组（循环血小板：2.41±0.14 对 2.87±0.09，P=0.014；单核细胞：8.57±1.20 对 12.3±0.57，P=0.006；粒细胞：4.30±0.65 对 6.50±0.34，P=0.005）。年龄校正后，血小板 CD147 表达与 CAD 之间的关联消失，但白细胞 CD147 表达与 CAD 之间的关联仍然存在。多变量分析显示，血小板 CD147 表达的独立预测因子为单核细胞 CD147 表达、NLR 和年龄。
体内可见血小板 CD147 表达，并与传统血小板活化标志物及白细胞 CD147 表达呈中度相关。血小板 CD147 表达与年龄的相关性更强，而白细胞 CD147 表达与临床 CAD 的相关性更强，提示体内血小板和白细胞 CD147 表达的调控存在差异。
